1.Emmerich J, Hu Q, Hanke N, Hartmann RW.. (2013) Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type., 56 (15):[PMID:23869452][10.1021/jm400240r]
2.Hu Q, Kunde J, Hanke N, Hartmann RW.. (2015) Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase., 96 [PMID:25874338][10.1016/j.ejmech.2015.04.013]
3.Emmerich J, van Koppen CJ, Burkhart JL, Hu Q, Siebenbürger L, Boerger C, Scheuer C, Laschke MW, Menger MD, Hartmann RW.. (2017) Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease., 60 (12):[PMID:28570067][10.1021/acs.jmedchem.7b00437]